08:46 AM EDT, 10/24/2025 (MT Newswires) -- Genenta Science (GNTA) said Friday that it has partnered with Anemocyte to advance an off-the-shelf lentiviral vector plasmid DNA platform, which is a set of processes for producing the high-quality plasmid DNA to manufacture lentiviral vectors for gene therapy.

The immuno-oncology company said the agreement builds on the companies' prior plasmid DNA work and centers on Genenta's LVV technology.

Anemocyte will use the platform to supply materials ranging from research to GMP-grade across preclinical and commercial stages, Genenta said.

Financial details of the partnership were not disclosed.

Shares of Genenta were up 250% in recent Friday premarket activity.